Home/Pipeline/Autologous Cell Therapy (likely TIL)

Autologous Cell Therapy (likely TIL)

Solid Tumors

Pre-clinicalActive

Key Facts

Indication

Solid Tumors

Phase

Pre-clinical

Status

Active

Company

BioCytics

About BioCytics

BioCytics is a North Carolina-based biotech company with a dual business model combining internal cell therapy development with external contract services. Its internal pipeline centers on autologous immune cell therapies, particularly Tumor-Infiltrating Lymphocytes (TILs), for solid tumors, having recently achieved a key regulatory milestone with an FDA INTERACT meeting. Externally, the company generates revenue and de-risks its platform by providing CDMO, CRO, and biobanking services to industry partners, leveraging its expertise in cell therapy process development and GMP manufacturing.

View full company profile

Therapeutic Areas

Oncology

Other Solid Tumors Drugs

Drug	Company	Phase	Status
APVO603	Aptevo Therapeutics	Preclinical	Active
APVO711	Aptevo Therapeutics	Preclinical	Active
Platform-derived Immunotherapy	GenCirq	Pre-clinical	Active
DM001	Domabio	Phase 1	Active (IND cleared in US and China)
DM002	Domabio	Phase 1	Active (IND cleared in US)
DM005	Domabio	Phase 1	Active (IND cleared in US, Australia, and China; first patient dosed in US)
SP-2-225	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
SP-1-161	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
CAR-T Solid Tumor Program	Carina Biotech	Phase 1/2a	Active
HBM1020	Harbour BioMed	Phase 1	Active (Global)
HBM7022	Harbour BioMed	Phase 1	Out-Licensed
HBM9033	Harbour BioMed	Discovery	Out-Licensed